Atlas Trials

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

Clinical trial NCT04923048 · UNKNOWN

Trial details

NCT number
NCT04923048
Sponsor
Genor Biopharma Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
B Cell NHLCLL
Start date
2021-08-31
Primary completion
2024-06-28
Enrollment
460

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.